Mendel Money Management’s Pfizer PFE Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | – | Sell |
-8,000
| Closed | -$225K | – | 137 |
|
|
2026
Q1 | $225K | Sell |
8,000
-3,815
| -32% | -$102K | 0.09% | 134 |
|
|
2025
Q4 | $294K | Sell |
11,815
-4,445
| -27% | -$112K | 0.12% | 129 |
|
|
2025
Q3 | $414K | Sell |
16,260
-1,997
| -11% | -$49.3K | 0.17% | 114 |
|
|
2025
Q2 | $443K | Sell |
18,257
-400
| -2% | -$9.33K | 0.2% | 105 |
|
|
2025
Q1 | $473K | Hold |
18,657
| – | – | 0.22% | 101 |
|
|
2024
Q4 | $495K | Buy |
18,657
+170
| +0.9% | +$4.61K | 0.22% | 96 |
|
|
2024
Q3 | $535K | Buy |
18,487
+620
| +3% | +$18.1K | 0.23% | 96 |
|
|
2024
Q2 | $500K | Sell |
17,867
-565
| -3% | -$15.6K | 0.23% | 89 |
|
|
2024
Q1 | $511K | Buy |
18,432
+5,780
| +46% | +$160K | 0.24% | 86 |
|
|
2023
Q4 | $364K | Sell |
12,652
-1,820
| -13% | -$55K | 0.18% | 107 |
|
|
2023
Q3 | $480K | Sell |
14,472
-485
| -3% | -$17.2K | 0.26% | 77 |
|
|
2023
Q2 | $549K | Sell |
14,957
-422
| -3% | -$16.4K | 0.28% | 70 |
|
|
2023
Q1 | $627K | Sell |
15,379
-868
| -5% | -$37.5K | 0.34% | 60 |
|
|
2022
Q4 | $832K | Sell |
16,247
-395
| -2% | -$18.9K | 0.47% | 49 |
|
|
2022
Q3 | $728K | Buy |
16,642
+1,871
| +13% | +$90.9K | 0.45% | 52 |
|
|
2022
Q2 | $774K | Sell |
14,771
-1,788
| -11% | -$91.1K | 0.46% | 48 |
|
|
2022
Q1 | $857K | Buy |
16,559
+8,934
| +117% | +$464K | 0.42% | 49 |
|
|
2021
Q4 | $450K | Sell |
7,625
-1,380
| -15% | -$68.4K | 0.26% | 51 |
|
|
2021
Q3 | $387K | Buy |
9,005
+95
| +1% | +$4.21K | 0.24% | 54 |
|
|
2021
Q2 | $349K | Sell |
8,910
-70
| -0.8% | -$2.72K | 0.22% | 53 |
|
|
2021
Q1 | $325K | Sell |
8,980
-740
| -8% | -$26.3K | 0.21% | 52 |
|
|
2020
Q4 | $358K | Buy |
9,720
+213
| +2% | +$7.81K | 0.25% | 49 |
|
|
2020
Q3 | $331K | Sell |
9,507
-158
| -2% | -$5.54K | 0.26% | 47 |
|
|
2020
Q2 | $300K | Buy |
+9,665
| New | +$328K | 0.26% | 47 |
|
|
2019
Q4 | $344K | Buy |
9,244
+159
| +2% | +$5.66K | 0.3% | 43 |
|
|
2019
Q3 | $310K | Sell |
9,085
-8,844
| -49% | -$322K | 0.29% | 44 |
|
|
2019
Q2 | $737K | Buy |
+17,929
| New | +$712K | 0.71% | 32 |
|
|
2018
Q3 | $657K | Buy |
+15,705
| New | +$605K | 0.64% | 30 |
|
|
2017
Q4 | $802K | Buy |
+23,324
| New | +$795K | 0.77% | 30 |
|
Other funds holding PFE
Mendel Money Management's PFE Position: Q2 2026 in Review
Mendel Money Management sold out of Pfizer (PFE) in Q2 2026, closing a stake of 8,000 shares — an estimated $225K sold.
Mendel Money Management first reported a position in PFE in Q4 2017 and held it in 29 quarters. The position peaked at $857K in Q1 2022. 2,834 funds tracked by Wall St. Rank hold PFE as of Q2 2026.
- Mendel Money Management reported no remaining Pfizer position as of Q2 2026 after selling out during the quarter.
- Mendel Money Management sold 8,000 Pfizer shares in Q2 2026, an estimated $225K.
- Mendel Money Management first reported a position in Pfizer in Q4 2017 and held it in 29 quarters.
- Mendel Money Management's Pfizer position peaked at $857K in Q1 2022.
- 2,834 funds tracked by Wall St. Rank held Pfizer as of Q2 2026.
Based on Mendel Money Management's 13F filing for Q2 2026, filed 30 Jul 2026.